Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical…
90,750€
0,55%
Echtzeit-Aktienkurs Arena Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Arena Pharmaceuticals Inc. Aktie
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
…
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript
…
Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda
Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to receive regulatory…
Deep Track Capitals Strategic Investment in Reneo Pharmaceuticals
On October 4, 2024, Deep Track Capital, LP (Trades, Portfolio) marked a significant portfolio addition by acquiring 68,415.6 shares of…
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript
…
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
…
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged…
Pfizer: AbbVie, Bristol-Myers, Eli Lilly, Johnson & Johnson, Takeda - Die Konkurrenz ist enorm - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…
Pfizer: Enorme Konkurrenz
Mitte Dezember 2021 hat Pfizer die milliardenschwere Übernahme von Arena Pharmaceuticals verkündet und sich somit den Zugriff auf die Substanz…
Pfizer: Enorme Konkurrenz
Mitte Dezember 2021 hat Pfizer die milliardenschwere Übernahme von Arena Pharmaceuticals verkündet und sich somit den Zugriff auf die Substanz…
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
…
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Call Transcript
…
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…
Vanda Pharmaceuticals Inc. (VNDA) Q3 2023 Earnings Call Transcript
…
Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript
…
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call Transcript
…
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…